LQDA
$36.86
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formu...
Recent News
Zacks Industry Outlook Highlights Terns Pharmaceuticals, ADMA Biologics, ANI Pharmaceuticals and Liquidia
Biotech momentum in 2026 spotlights companies like Liquidia and ANI Pharmaceuticals as pipeline innovation, drug demand and rising M&A activity drive sector interest.
4 Biotech Stocks to Watch for Potential Upside in 2026
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position TERN, ADMA, ANIP and LQDA in this volatile sector.
Dave Stock Soars 150% in a Year as Newly Disclosed $7 Million Buy Signals Confidence in Fintech Upstart
Dave Inc. delivers digital banking and personal finance tools designed to offer alternatives to traditional banking platforms.
Best Momentum Stocks to Buy for March 10th
STRL, LQDA and NWPX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 10th, 2026.
A Look At Liquidia (LQDA) Valuation After YUTREPIA Powered Revenue Growth And Profitability Shift
Liquidia (LQDA) is back in focus after reporting fourth quarter and full year 2025 results, with quarterly revenue of US$92.02 million and net income of US$14.56 million, supported by strong YUTREPIA uptake. See our latest analysis for Liquidia. Liquidia’s recent earnings release and shelf registrations have come after a volatile stretch, with a 12.11% 7 day share price return, a 25.97% 1 month share price decline, and a very large 5 year total shareholder return. This suggests long term...